« Back
Home /
HDAC8-IN-1

HDAC8-IN-1

Item no.	HY-111342-10mg
Manufacturer	MedChem Express
CASRN	1417997-93-3
Amount	10 mg
Quantity options	100 mg 10 mM/1 mL 10 mg 1 mg 25 mg 50 mg 5 mg
Category	Oncology Neuroscience Neural Epigenetics Inhibitors & Compound Libraries Small Molecules By Organ Lung Cancer
Type	Inhibitors
Specific against	other
Purity	99.77
Citations	[1]Huang WJ, et al. Synthesis and biological evaluation of ortho-aryl N-hydroxycinnamides as potent histone deacetylase (HDAC) 8 isoform-selective inhibitors. ChemMedChem. 2012 Oct;7(10):1815-24.\|[2]Cui J, et al., IL-4 inhibits regulatory T cells differentiation by HDAC9-mediated epigenetic regulation. Cell Death Dis. 2021 May 18;12(6):501.
Smiles	O=C(NO)/C=C/C1=CC=C(OC)C=C1C2=CC=C(C3=CC=CC=C3)C=C2
ECLASS 10.1	32160490
ECLASS 11.0	32160490
UNSPSC	12000000
Alias	1417997-93-3
Shipping Condition	Room temperature
Available
Manufacturer - Type	Reference compound
Manufacturer - Applications	Cancer-programmed cell death
Manufacturer - Targets	HDAC
Shipping Temperature	Room Temperature
Storage Conditions	-20°C, 3 years; 4°C, 2 years (Powder)
Molecular Weight	345.39
Product Description	HDAC8-IN-1 is a HDAC8 inhibitor with an IC50 of 27.2 nM.
Manufacturer - Research Area	Cancer
Solubility	DMSO: 50 mg/mL (ultrasonic; warming; heat to 60°C)
Manufacturer - Pathway	Cell Cycle/DNA Damage; Epigenetics
Isoform	HDAC8
Clinical information	No Development Reported

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Request Data Sheet

Request product datasheet

HY-111342-10mg-safety-datasheet.pdf